Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
Lung cancer is the third most common cancer and the leading cause of cancer-related deaths in the U.S., and according to the ...
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t ...
The FDA's so-called complete response letter was related to observations as part of a standard pre-approval inspection at a ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease ...
News Medical on MSN6d
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancerThe highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback